Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous fosfomycin for complicated urinary tract infections due to third-generation cephalosporin-resistant Enterobacterales
2023-000052-38Phase 4Active
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of fosfomycin in complicated urinary tract infection (cUTI) (2 arms), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Clinical Response (CR). Started Jan 2023; status: active.
02
Drugs
fosfomycin
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on 2023-000052-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000052-38.